Centre asks Serum Institute, Bharat Biotech to lower prices of Covishield, Covaxin: Sources

Ad 30s Skip Ad in 5s -Skip Ad-
Visit advertiser site
  • Govt rejects Serum Institute of India’s request to export 50 lakh doses of Covishield vaccine to UK

    Govt rejects Serum Institute of India’s request to export 50 lakh doses of Covishield vaccine to UK

    Amid reports of Covid-19 vaccine shortage across the country, the Modi government has refused to allow Serum Institute of India (SII) to export around 50 lakh doses of Covishield vaccine to the United Kingdom. While rejecting SII’s request, the central government insisted that the local vaccine production be supplied to protect Indians first.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Govt rejects Serum Institute of India’s request to export 50 lakh doses of Covishield vaccine to UK

    By The Economic Times| 245 views

  • Covishield Price Drop : Serum Institute ने कोविशील्ड का घटाया दाम, 300 में मिलेगी कोरोना की वैक्सीन

    Covishield Price Drop : Serum Institute ने कोविशील्ड का घटाया दाम, 300 में मिलेगी कोरोना की वैक्सीन

    Serum Institute ने कोविशील्ड का घटाया दाम, राज्यों को अब 300 में मिलेगी कोरोना की वैक्सीन

    Visit Us - http://www.inhnews.in/​​​​

    Follow Us On Twitter - https://twitter.com/inhnewsindia​​​​

    Our WhatsApp Number - 9993022843

    Link - https://youtu.be/XVOd1wWkhx8

    Incoming Search Terms,

    #COVIDSecondWave​ #CoronavirusVaccine​

    COVID-19 Vaccine News,
    Corona Vaccine,
    Covid-19 vaccination,
    Corona Vaccine In India,
    COVID-19 Vaccine in India,
    COVID-19 vaccination in India,
    COVID Second Wave in India,
    Corona Second Wave,
    Corona Virus Outbreak in India,
    Corona Virus in India,
    Latest News,

    Covishield Price Drop : Serum Institute ने कोविशील्ड का घटाया दाम, 300 में मिलेगी कोरोना की वैक्सीन

    By Inh News| 136 views

  • Serum fixes 'Covishield' prices at Rs 400 per dose for state govts, Rs 600 for private hospitals

    Serum fixes 'Covishield' prices at Rs 400 per dose for state govts, Rs 600 for private hospitals

    Serum Institute of India (SII), the world's largest vaccine maker, on Wednesday announced a price of Rs 600 per dose for COVID vaccine supplies to private hospitals and Rs 400 per dose to state governments. In a statement posted on its Twitter handle, SII said it will address the limited capacity by scaling up the vaccine production over the next two months.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Serum fixes 'Covishield' prices at Rs 400 per dose for state govts, Rs 600 for private hospitals

    By The Economic Times| 453 views

  • Coronavirus : कोरोनावायरस की तीसरी लहर से Bharat Biotech की 'Covaxin' बचाएगी बच्चों को !

    Coronavirus : कोरोनावायरस की तीसरी लहर से Bharat Biotech की 'Covaxin' बचाएगी बच्चों को !

    कोरोनावायरस : भारत में कोरोनावायरस संक्रमण की तीसरी लहर इस साल सर्दियों के मौसम यानी नवंबर के अंत और दिसंबर की शुरुआत में आने की संभावना है। हेल्थ एक्सपर्ट्स का कहना है कि यह तीसरी लहर बच्चों के लिए ज़्यादा खतरनाक होगी। इस खबर ने पेरेंट्स की चिंता को बढ़ा दिया था क्योंकि देश में बच्‍चों के लिए कोरोना वायरस की कोई वैक्‍सीन अभी उपलब्‍ध नहीं है। लेकिन इस बीच बड़ी खुशखबरी ये मिल रही है कि जल्द ही 2 साल से 18 साल तक के बच्चों के लिए आने वाले दिन में कोरोना की वैक्सीन मिल सकती है। भारत बायोटेक की कोवैक्सीन जल्द ही बच्चों के लिए भी उपलब्ध हो जाएगी। आधिकारिक सूत्रों ने कहा है कि मंगलवार को सेंट्रल ड्रग्स स्टैंडर्ड कंट्रोल आर्गेनाईजेशन यानी (CDSCO ) की एक विशेष पैनल ने भारत बायोटेक की कोवाक्सिन को 2 से 18 साल की उम्र के ट्रायल के लिए मंजूरी दे दी है। यह ट्रायल विभिन्न जगहों पर 525 बच्चों पर होगा, जिनमें एम्स दिल्ली, एम्स पटना और मेडिट्रिना इंस्टीट्यूट ऑफ मेडिकल साइंसेज, नागपुर शामिल हैं। कोवैक्सीन पूरी तरह से स्वदेशी है, जिसे भारत बायोटेक ने बनाया है। अभी तक यह वैक्सीन 18 साल से ऊपर से लोगों के लिए ही बनाई गई है।

    To Subscribe on Youtube: 

    https://www.youtube.com/user/punjabkesaritv

    Follow us on Twitter :
    https://twitter.com/punjabkesari

    Like us on FB:
     https://www.facebook.com/Pkesarionline/

    Coronavirus : कोरोनावायरस की तीसरी लहर से Bharat Biotech की 'Covaxin' बचाएगी बच्चों को !

    By PunjabKesari TV| 375 views

  • Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News

    Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News

    Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News


    Subject Expert Committee (SEC) gave nod to Bharat Biotech’s ‘Covaxin’ for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the ‘Covaxin’ is being used in adults. ‘Covaxin’ is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.


    #BharatBiotech​ #Covaxin​ #CovidVaccine​ #catchnews #CatchNewsToday

    For more videos, subscribe to our channel: https://goo.gl/bkDSLj
    Check out Catch News for more news: http://www.catchnews.com/

    Follow Catch News here -
    Facebook:https://bit.ly/2xD3NKZ
    Twitter: https://bit.ly/2NG3rhr
    Instagram: https://bit.ly/30mh2vE
    --------------------------------------------------------------------------------------------
    Also, Follow Catch in Hindi: http://hindi.catchnews.com/

    Catch is a contemporary new digital platform about the ideas and events shaping the world. It aims to filter and provide news-on-the-run for an impatient new generation. It offers greater insight for influencers and the deeper consumer of news. When opinions are shrill and polarized, we hope to create a middle ground and build bridges. When there is a set thinking, we hope to stand apart and go against the wind. The world is complex, exciting, layered, evolving, always interesting. We hope to be the same.

    Lots of videos and lots more in the pipeline. Stay tuned.

    Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News

    By Catch News| 170 views

  • Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds

    Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds

    Subject Expert Committee (SEC) gave nod to Bharat Biotech’s ‘Covaxin’ for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the ‘Covaxin’ is being used in adults. ‘Covaxin’ is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds

    By The Economic Times| 112 views

  • 100 Covaxin sites will shut down as Bharat Biotech unable to provide more doses, says Manish Sisodia

    100 Covaxin sites will shut down as Bharat Biotech unable to provide more doses, says Manish Sisodia

    Deputy Chief Minister of Delhi, Manish Sisodia said, 'Bharat Biotech wrote to us that they could not give us more doses, the central government is controlling the supply of the vaccine. I would say exporting 6.6 cr doses was the biggest mistake, We are forced to shut down 100 Covaxin-vaccination sites in 17 schools due to no supply’. Listen in.


    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    100 Covaxin sites will shut down as Bharat Biotech unable to provide more doses, says Manish Sisodia

    By The Economic Times| 148 views

  • Bharat Biotech’s 'Covaxin' gets DCGI nod for phase 2, 3 clinical trials on children aged 2 to 18 yrs

    Bharat Biotech’s 'Covaxin' gets DCGI nod for phase 2, 3 clinical trials on children aged 2 to 18 yrs

    The Drugs Controller General of India (DCGI) on Thursday approved Phase 2 and 3 clinical trial of Bharat Biotech's COVAXIN vaccine in the age group of 2 to 18 years, informed the Ministry of Health and Family Welfare. Bharat Biotech will conduct trials in 525 healthy volunteers. "In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28," it said.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Bharat Biotech’s 'Covaxin' gets DCGI nod for phase 2, 3 clinical trials on children aged 2 to 18 yrs

    By The Economic Times| 186 views

  • Two PSUs enter into pact with Covaxin maker Bharat Biotech to produce Covid-19 vaccines

    Two PSUs enter into pact with Covaxin maker Bharat Biotech to produce Covid-19 vaccines

    Two government-owned companies have entered into an agreement with Bharat Biotech to share the vaccine formula in order to manufacture Covid-19 vaccines.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Two PSUs enter into pact with Covaxin maker Bharat Biotech to produce Covid-19 vaccines

    By The Economic Times| 465 views

Replay
The Economic Times's image
Published on: May 5, 2021
233 views

The central government has asked the Serum Institute of India and Bharat Biotech to lower the price of COVID vaccines, Covishield and Covaxin as India gears up to vaccinate all aged above 18 from May 1, official sources said on Monday.

► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

► http://EconomicTimes.com

► For business news on the go, download ET app:
https://etapp.onelink.me/tOvY/EconomicTimesApp

Follow ET on:

► Facebook - https://www.facebook.com/EconomicTimes
► Twitter - http://www.twitter.com/economictimes
► LinkedIn - http://www.linkedin.com/company/economictimes
► Instagram - https://www.instagram.com/the_economic_times
► Flipboard - https://flipboard.com/@economictimes

Centre asks Serum Institute, Bharat Biotech to lower prices of Covishield, Covaxin: Sources

#businessnews#economynews#economictimes#ETMarkets#coronavirus#covid19#covaxin#BharatBiotech#covishield#Covidvaccines#SerumInstituteofIndiaSII


Category:

News

Show More [+]
Show Less [-]
Size : x pixels
0 comments founds
No comments received yet, Be first to add comment.
  • Govt rejects Serum Institute of India’s request to export 50 lakh doses of Covishield vaccine to UKUp next

    Govt rejects Serum Institute of India’s request to export 50 lakh doses of Covishield vaccine to UK

    Amid reports of Covid-19 vaccine shortage across the country, the Modi government has refused to allow Serum Institute of India (SII) to export around 50 lakh doses of Covishield vaccine to the United Kingdom. While rejecting SII’s request, the central government insisted that the local vaccine production be supplied to protect Indians first.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Govt rejects Serum Institute of India’s request to export 50 lakh doses of Covishield vaccine to UK

    By The Economic Times| 245 views

  • Covishield Price Drop : Serum Institute ने कोविशील्ड का घटाया दाम, 300 में मिलेगी कोरोना की वैक्सीन

    Covishield Price Drop : Serum Institute ने कोविशील्ड का घटाया दाम, 300 में मिलेगी कोरोना की वैक्सीन

    Serum Institute ने कोविशील्ड का घटाया दाम, राज्यों को अब 300 में मिलेगी कोरोना की वैक्सीन

    Visit Us - http://www.inhnews.in/​​​​

    Follow Us On Twitter - https://twitter.com/inhnewsindia​​​​

    Our WhatsApp Number - 9993022843

    Link - https://youtu.be/XVOd1wWkhx8

    Incoming Search Terms,

    #COVIDSecondWave​ #CoronavirusVaccine​

    COVID-19 Vaccine News,
    Corona Vaccine,
    Covid-19 vaccination,
    Corona Vaccine In India,
    COVID-19 Vaccine in India,
    COVID-19 vaccination in India,
    COVID Second Wave in India,
    Corona Second Wave,
    Corona Virus Outbreak in India,
    Corona Virus in India,
    Latest News,

    Covishield Price Drop : Serum Institute ने कोविशील्ड का घटाया दाम, 300 में मिलेगी कोरोना की वैक्सीन

    By Inh News| 136 views

  • Serum fixes 'Covishield' prices at Rs 400 per dose for state govts, Rs 600 for private hospitals

    Serum fixes 'Covishield' prices at Rs 400 per dose for state govts, Rs 600 for private hospitals

    Serum Institute of India (SII), the world's largest vaccine maker, on Wednesday announced a price of Rs 600 per dose for COVID vaccine supplies to private hospitals and Rs 400 per dose to state governments. In a statement posted on its Twitter handle, SII said it will address the limited capacity by scaling up the vaccine production over the next two months.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Serum fixes 'Covishield' prices at Rs 400 per dose for state govts, Rs 600 for private hospitals

    By The Economic Times| 453 views

  • Coronavirus : कोरोनावायरस की तीसरी लहर से Bharat Biotech की 'Covaxin' बचाएगी बच्चों को !

    Coronavirus : कोरोनावायरस की तीसरी लहर से Bharat Biotech की 'Covaxin' बचाएगी बच्चों को !

    कोरोनावायरस : भारत में कोरोनावायरस संक्रमण की तीसरी लहर इस साल सर्दियों के मौसम यानी नवंबर के अंत और दिसंबर की शुरुआत में आने की संभावना है। हेल्थ एक्सपर्ट्स का कहना है कि यह तीसरी लहर बच्चों के लिए ज़्यादा खतरनाक होगी। इस खबर ने पेरेंट्स की चिंता को बढ़ा दिया था क्योंकि देश में बच्‍चों के लिए कोरोना वायरस की कोई वैक्‍सीन अभी उपलब्‍ध नहीं है। लेकिन इस बीच बड़ी खुशखबरी ये मिल रही है कि जल्द ही 2 साल से 18 साल तक के बच्चों के लिए आने वाले दिन में कोरोना की वैक्सीन मिल सकती है। भारत बायोटेक की कोवैक्सीन जल्द ही बच्चों के लिए भी उपलब्ध हो जाएगी। आधिकारिक सूत्रों ने कहा है कि मंगलवार को सेंट्रल ड्रग्स स्टैंडर्ड कंट्रोल आर्गेनाईजेशन यानी (CDSCO ) की एक विशेष पैनल ने भारत बायोटेक की कोवाक्सिन को 2 से 18 साल की उम्र के ट्रायल के लिए मंजूरी दे दी है। यह ट्रायल विभिन्न जगहों पर 525 बच्चों पर होगा, जिनमें एम्स दिल्ली, एम्स पटना और मेडिट्रिना इंस्टीट्यूट ऑफ मेडिकल साइंसेज, नागपुर शामिल हैं। कोवैक्सीन पूरी तरह से स्वदेशी है, जिसे भारत बायोटेक ने बनाया है। अभी तक यह वैक्सीन 18 साल से ऊपर से लोगों के लिए ही बनाई गई है।

    To Subscribe on Youtube: 

    https://www.youtube.com/user/punjabkesaritv

    Follow us on Twitter :
    https://twitter.com/punjabkesari

    Like us on FB:
     https://www.facebook.com/Pkesarionline/

    Coronavirus : कोरोनावायरस की तीसरी लहर से Bharat Biotech की 'Covaxin' बचाएगी बच्चों को !

    By PunjabKesari TV| 375 views

  • Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News

    Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News

    Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News


    Subject Expert Committee (SEC) gave nod to Bharat Biotech’s ‘Covaxin’ for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the ‘Covaxin’ is being used in adults. ‘Covaxin’ is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.


    #BharatBiotech​ #Covaxin​ #CovidVaccine​ #catchnews #CatchNewsToday

    For more videos, subscribe to our channel: https://goo.gl/bkDSLj
    Check out Catch News for more news: http://www.catchnews.com/

    Follow Catch News here -
    Facebook:https://bit.ly/2xD3NKZ
    Twitter: https://bit.ly/2NG3rhr
    Instagram: https://bit.ly/30mh2vE
    --------------------------------------------------------------------------------------------
    Also, Follow Catch in Hindi: http://hindi.catchnews.com/

    Catch is a contemporary new digital platform about the ideas and events shaping the world. It aims to filter and provide news-on-the-run for an impatient new generation. It offers greater insight for influencers and the deeper consumer of news. When opinions are shrill and polarized, we hope to create a middle ground and build bridges. When there is a set thinking, we hope to stand apart and go against the wind. The world is complex, exciting, layered, evolving, always interesting. We hope to be the same.

    Lots of videos and lots more in the pipeline. Stay tuned.

    Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News

    By Catch News| 170 views

  • Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds

    Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds

    Subject Expert Committee (SEC) gave nod to Bharat Biotech’s ‘Covaxin’ for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the ‘Covaxin’ is being used in adults. ‘Covaxin’ is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds

    By The Economic Times| 112 views

  • 100 Covaxin sites will shut down as Bharat Biotech unable to provide more doses, says Manish Sisodia

    100 Covaxin sites will shut down as Bharat Biotech unable to provide more doses, says Manish Sisodia

    Deputy Chief Minister of Delhi, Manish Sisodia said, 'Bharat Biotech wrote to us that they could not give us more doses, the central government is controlling the supply of the vaccine. I would say exporting 6.6 cr doses was the biggest mistake, We are forced to shut down 100 Covaxin-vaccination sites in 17 schools due to no supply’. Listen in.


    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    100 Covaxin sites will shut down as Bharat Biotech unable to provide more doses, says Manish Sisodia

    By The Economic Times| 148 views

  • Bharat Biotech’s 'Covaxin' gets DCGI nod for phase 2, 3 clinical trials on children aged 2 to 18 yrs

    Bharat Biotech’s 'Covaxin' gets DCGI nod for phase 2, 3 clinical trials on children aged 2 to 18 yrs

    The Drugs Controller General of India (DCGI) on Thursday approved Phase 2 and 3 clinical trial of Bharat Biotech's COVAXIN vaccine in the age group of 2 to 18 years, informed the Ministry of Health and Family Welfare. Bharat Biotech will conduct trials in 525 healthy volunteers. "In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28," it said.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Bharat Biotech’s 'Covaxin' gets DCGI nod for phase 2, 3 clinical trials on children aged 2 to 18 yrs

    By The Economic Times| 186 views

  • Two PSUs enter into pact with Covaxin maker Bharat Biotech to produce Covid-19 vaccines

    Two PSUs enter into pact with Covaxin maker Bharat Biotech to produce Covid-19 vaccines

    Two government-owned companies have entered into an agreement with Bharat Biotech to share the vaccine formula in order to manufacture Covid-19 vaccines.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Two PSUs enter into pact with Covaxin maker Bharat Biotech to produce Covid-19 vaccines

    By The Economic Times| 465 views

The Economic Times

  • From priority to allocation criteria: Centre releases revised guidelines for COVID vaccination drive

    From priority to allocation criteria: Centre releases revised guidelines for COVID vaccination drive

    Govt of India releases revised guidelines for national COVID vaccination program, to be implemented from June 21. "Vaccine doses to be allocated to States/UTs based on population, disease burden & vaccination' progress. Wastage will affect allocation negatively," guidelines say.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    From priority to allocation criteria: Centre releases revised guidelines for COVID vaccination drive

    By The Economic Times| 64910 views

  • Suvendu Adhikari meets HM Amit Shah amid reports of post-poll violence in Bengal

    Suvendu Adhikari meets HM Amit Shah amid reports of post-poll violence in Bengal

    Leader of Opposition in the West Bengal Assembly and BJP MLA Suvendu Adhikari called on Union Home Minister Amit Shah in Delhi amid reports of post-poll violence in Bengal.

    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Suvendu Adhikari meets HM Amit Shah amid reports of post-poll violence in Bengal

    By The Economic Times| 1160 views

  • Uttar Pradesh: 22 patients die during alleged 'mock oxygen drill' at Agra hospital, probe on

    Uttar Pradesh: 22 patients die during alleged 'mock oxygen drill' at Agra hospital, probe on

    22 Covid & non-Covid patients allegedly died following a 'mock oxygen drill' in UP. A viral video purportedly of a hospital owner in Agra has sparked a major controversy. In the video, the man is heard saying that he got oxygen supply from patients snapped for 5 mins. The man, in the video, added that this was part of an experiment to know who all will survive. Reports suggest the video is purportedly of Arinjay Jain, owner of Paras Hospital on NH 2. UP health dept has ordered a probe into the incident after the video went viral.



    ► Subscribe to The Economic Times for latest video updates. It's free! - http://www.youtube.com/TheEconomicTimes?sub_confirmation=1

    ► More Videos @ ETTV - http://economictimes.indiatimes.com/TV

    ► http://EconomicTimes.com

    ► For business news on the go, download ET app:
    https://etapp.onelink.me/tOvY/EconomicTimesApp

    Follow ET on:

    ► Facebook - https://www.facebook.com/EconomicTimes
    ► Twitter - http://www.twitter.com/economictimes
    ► LinkedIn - http://www.linkedin.com/company/economictimes
    ► Instagram - https://www.instagram.com/the_economic_times
    ► Flipboard - https://flipboard.com/@economictimes

    Uttar Pradesh: 22 patients die during alleged 'mock oxygen drill' at Agra hospital, probe on

    By The Economic Times| 1165 views

Govt./PSU

Daily Mirror

  • Nitish Kumar की जगह Jitan Ram Manjhi को CM बनाएंगे BJP ! Mukesh Sahani | Bihar News | #dblive

    Nitish Kumar की जगह Jitan Ram Manjhi को CM बनाएंगे BJP ! Mukesh Sahani | Bihar News | #dblive

    Nitish Kumar की जगह Jitan Ram Manjhi को CM बनाएंगे BJP ! Mukesh Sahani | Bihar News | #dblive

    #HindiNews | #BreakingNews | #Watch | #video |

    Get paid membership : https://www.youtube.com/channel/UCBbpLKJLhIbDd_wX4ubU_Cw/join
    DB LIVE APP : https://play.google.com/store/apps/details?id=dblive.tv.news.dblivetv.com
    DB LIVE TV : http://dblive.tv/
    SUBSCRIBE TO OUR CHANNEL: https://www.youtube.com/channel/UCBbpLKJLhIbDd_wX4ubU_Cw
    DESHBANDHU : http://www.deshbandhu.co.in/
    FACEBOOK : https://www.facebook.com/DBlivenews/
    TWITTER : https://twitter.com/dblive15
    ENTERTAINMENT LIVE : https://www.youtube.com/channel/UCyX4qQhpz8WQP2Iu7jzHGFQ
    Sports Live : https://www.youtube.com/channel/UCHgCkbxlMRgMrjUtvMmBojg

    Nitish Kumar की जगह Jitan Ram Manjhi को CM बनाएंगे BJP ! Mukesh Sahani | Bihar News | #dblive

    By DB Live| 0 views

  • BJP MLA Ganpat Gaikwad ने Eknath Shinde Shiv Sena Leader Mahesh Gaikwad को थाने के अंदर मारी गोलियां

    BJP MLA Ganpat Gaikwad ने Eknath Shinde Shiv Sena Leader Mahesh Gaikwad को थाने के अंदर मारी गोलियां

    #ganpatgaikwad #maheshgaikwad #eknathshinde

    गोलियों की तड़तड़ाहट... भागते... जान बचाते लोग.... बीजेपी नेता की आंखों में खून सवार... ये वीडियो कहीं और का नहीं बल्कि बीजेपी के नेतृत्व में बनी एकनाथ शिंदे सरकार के महाराष्ट्र राज्य का है... गोलियां मारने वाला कोई और नहीं बल्कि मौजूदा विधायक और बीजेपी का प्रतिष्ठित नेता है... सत्ता की हनक ऐसी कि थाने के अंदर गोलियां दाग रहा है...

    Subscribe to our YouTube channel: https://bit.ly/PunjabKesariTV

    Also, Watch ►
    Latest News & Updates ► https://bit.ly/PunjabKesariTVLatestNews
    Latest News On Jammu & Kashmir ► https://bit.ly/JammuKashmirNews
    Delhi News Updates | Punjab Kesari TV ► https://bit.ly/LatestDelhiNewsUpdates
    Latest Updates On West Bengal ► https://bit.ly/LatestWestBengalNews
    Viral Videos | Punjab Kesari TV ► https://bit.ly/LatestViralVideos
    Punjab Kesari National | Latest News & Updates ► https://bit.ly/LatestNationalNews
    Exclusive Interviews ► https://bit.ly/PunjabKesariTV-ExclusiveInterviews
    Russia Ukraine Crisis Live Updates ► https://bit.ly/UkraineRussiaCrisisUpdates
    Latest Updates On International News ► https://bit.ly/LatestInternationalNews

    Follow us on Twitter: https://twitter.com/punjabkesari
    Like us on FB: https://www.facebook.com/Pkesarionline/

    BJP MLA Ganpat Gaikwad ने Eknath Shinde Shiv Sena Leader Mahesh Gaikwad को थाने के अंदर मारी गोलियां

    By PunjabKesari TV| 0 views

  • Jummah की नमाज को लेकर Kashi में Police Alert, चप्पे- चप्पे पर Force तैनात

    Jummah की नमाज को लेकर Kashi में Police Alert, चप्पे- चप्पे पर Force तैनात

    #gyanvapicase #uttarpradesh #varanasi #policealert #jummah #Friday prayers
    Jummah की नमाज को लेकर Kashi में Police Alert, चप्पे- चप्पे पर Force तैनात
    #gyanvapicase #uttarpradesh #varanasi #policealert #jummah #Friday prayers #pictures #forces deployed #corner #regarding #Gyanvapi complex #policemen #Manduadih police station # in-chargeBharat Upadhyay #patrolled # Bansfatak area #security arrangements #Gyanvapi #Police Commissioner Mutha Ashok Jain #security #arrangements #sensitive places #experience #police #darshan puja started #Vyasji's basement #saint community #officials # Kashi Vidvat Parishad #performed #Gyan Talgriha #Gyan Talgrihnews #Committee #approved # five o'clock aarti # first aarti


    Follow Us On:

    Facebook : https://www.facebook.com/INDIALNV

    Twitter : https://twitter.com/india_lnv

    Instagram : https://www.instagram.com/lnv_india/Follow Us On:

    Facebook : https://www.facebook.com/INDIALNV

    Twitter : https://twitter.com/india_lnv

    Instagram : https://www.instagram.com/lnv_india/

    Jummah की नमाज को लेकर Kashi में Police Alert, चप्पे- चप्पे पर Force तैनात

    By LNV India| 0 views

  • Dehradun Live | विधानसभा में बोले रहे सीएम पुष्कर सिंह धामी उत्तराखंड विधानसभा सत्र का आगाज

    Dehradun Live | विधानसभा में बोले रहे सीएम पुष्कर सिंह धामी उत्तराखंड विधानसभा सत्र का आगाज

    #latestnewsupdates #breakingnews #news #uttrakhand #pushkarsinghdhami #budgetsession #bjp #vidhansabha #news #jantv

    Watch JAN TV on :
    Tata Play DTH : 1185
    Airtel DTH: 355
    JIO Fiber: 1384
    https://www.youtube.com/jantvindia/live

    Make sure you subscribe to our channel and never miss a new video:
    https://www.youtube.com/jantvindia
    https://www.facebook.com/jantvindia
    https://www.instagram.com/jantvindia/
    https://twitter.com/JANTV2012
    http://www.jantv.in

    Jan TV Live | Hindi News LIVE 24X7 | Jan TV Live | Hindi news 24X7 LIVE
    Jan TV | Hindi News Jan TV Live | Jan TV News | Jan TV Live
    News Credit -VKJ

    Dehradun Live | विधानसभा में बोले रहे सीएम पुष्कर सिंह धामी उत्तराखंड विधानसभा सत्र का आगाज

    By JANTV RAJASTHAN| 0 views

  • आज आएगा UP का Budget, Budget पेश करने से पहले होगी Yogi Cabinet की Meeting | UP Budget 2024-25

    आज आएगा UP का Budget, Budget पेश करने से पहले होगी Yogi Cabinet की Meeting | UP Budget 2024-25

    #UPBudget2024 #YogiAdityanath #SureshKumarKhanna

    आज आएगा UP का Budget, Budget पेश करने से पहले होगी Yogi Cabinet की Meeting | UP Budget 2024-25

    Subscribe to our YouTube channel: https://bit.ly/PunjabKesariTV

    Also, Watch ►
    Latest News & Updates ► https://bit.ly/PunjabKesariTVLatestNews
    Latest News On Jammu & Kashmir ► https://bit.ly/JammuKashmirNews
    Delhi News Updates | Punjab Kesari TV ► https://bit.ly/LatestDelhiNewsUpdates
    Latest Updates On West Bengal ► https://bit.ly/LatestWestBengalNews
    Viral Videos | Punjab Kesari TV ► https://bit.ly/LatestViralVideos
    Punjab Kesari National | Latest News & Updates ► https://bit.ly/LatestNationalNews
    Exclusive Interviews ► https://bit.ly/PunjabKesariTV-ExclusiveInterviews
    Russia Ukraine Crisis Live Updates ► https://bit.ly/UkraineRussiaCrisisUpdates
    Latest Updates On International News ► https://bit.ly/LatestInternationalNews

    Follow us on Twitter: https://twitter.com/punjabkesari
    Like us on FB: https://www.facebook.com/Pkesarionline/

    आज आएगा UP का Budget, Budget पेश करने से पहले होगी Yogi Cabinet की Meeting | UP Budget 2024-25

    By PunjabKesari TV| 0 views